Study of Inflammatory and Infection Markers in Periprosthetic Fluid: Correlation with Blood Analysis in Retrospective and Prospective Studies

Table 4

Risk factors for reconstruction failure in SSI patients.

	Reconstruction failure			OR (95% CI)
	Yes	No
	24	32
Age (years)			0.481	0.99 (0.95–1.03)	0.619
Age (>60 years)	8 (33.33%)	9 (28.13%)	0.772	1.28 (0.41–4.02)	0.675
BMI			0.230	1.04 (0.93–1.15)	0.527
BMI (>30)	4 (16.67%)	4 (12.90%)	0.718	1.35 (0.30–6.06)	0.695
Smoke ()	12 (50.00%)	8 (25.00%)	0.090	3.00 (0.97–9.30)	0.057
Diabetes	2 (8.33%)	0	0.179	1
Autoimmune pathologies	3 (12.50%)	2 (6.25%)	0.642	2.14 (0.33–13.96)	0.425
Chemotherapy	11 (45.83%)	16 (50.00%)	0.793	0.85 (0.29–2.44)	0.758
Neoadjuvant chemotherapy	0	3 (9.38%)	0.252	1
Adjuvant chemotherapy	11 (45.83%)	13 (40.63%)	0.788	1.24 (0.42–3.60)	0.697
Previous RT	2 (8.33%)	7 (21.88%)	0.274	0.32 (0.06–1.73)	0.187
RT	5 (20.83%)	8 (25.00%)	0.760	0.79 (0.22–2.81)	0.715
Expander brand (Mentor)	9 (37.50%)	8 (25.00%)	0.384	1.80 (0.57–5.69)	0.317
Expander volume (>500 mL)	11 (45.83%)	12 (37.50%)	0.590	1.41 (0.48–4.13)	0.531
Axillary dissection	11 (45.83%)	13 (40.63%)	0.788	1.24 (0.42–3.60)	0.697
Bilateral	2 (8.33%)	1 (3.13%)	0.571	2.82 (0.24–33.05)	0.409
Mstec (×10)			0.091	1.18 (0.99–1.42)	0.071
RMI			0.481	0.99 (0.96–1.03)	0.716
Total duration (×10)			0.344	1.12 (0.96–1.30)	0.158